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Oxytocin (OT) plays an important role in the onset of human labour by stimulating uterine contractions
and promoting prostaglandin/inﬂammatory cytokine synthesis in amnion via oxytocin receptor (OTR)
coupling. The OTR-antagonist, Atosiban, is widely used as a tocolytic for the management of acute
preterm labour. We found that in primary human amniocytes, Atosiban (10 mM) signals via PTX-sensitive
Gai to activate transcription factor NF-kB p65, ERK1/2, and p38 which subsequently drives upregulation
of the prostaglandin synthesis enzymes, COX-2 and phospho-cPLA2 and excretion of prostaglandins
(PGE2) (n ¼ 6; p < 0.05, ANOVA). Moreover, Atosiban treatment increased expression and excretion of the
inﬂammatory cytokines, IL-6 and CCL5. We also showed that OT-simulated activation of NF-kB, ERK1/2,
and p38 and subsequent prostaglandin and inﬂammatory cytokine synthesis is via Gai2 and Gai3 but
not Gaq, and is not inhibited by Atosiban. Activation or exacerbation of inﬂammation is not a desirable
effect of tocolytics. Therefore therapeutic modulation of the OT/OTR system for clinical management of
term/preterm labour should consider the effects of differential G-protein coupling of the OTR and the
role of OT or selective OTR agonists/antagonists in activating proinﬂammatory pathways.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Early preterm birth (<34 weeks gestation) accounts for the
majority of neonatal morbidity and mortality and is often associ-
ated with infection and/or inﬂammation. While uterine inﬂam-
mation can activate contractile pathways leading to preterm labour
(PTL) it also represents one of the most potent causes of cytokine
mediated cerebral injury in the neonate (Thornton et al., 2012). In
full term infants, chorioamnionitis and maternal infection areor; MAPK, mitogen activated
oupled receptor; PLC, phos-
ate; DAG, diacylglycerol; IP3,
p, Institute of Reproductive
Campus, Du Cane Road, East
idou).
Ireland Ltd. This is an open accessassociated with cerebral palsy and periventricular leucomalacia
(Grether and Nelson, 1997; Wu and Colford, 2000). Atosiban is a
nonapeptide, desamino-oxytocin analogue and a competitive
oxytocin/vasopressin receptor antagonist used clinically to reduce
uterine activity in threatened PTL (Goodwin et al., 1994; Usta et al.,
2011). Atosiban is generally considered to be a relatively safe
tocolytic with an improved adverse drug proﬁle to earlier tocolytics
such as ritrodrine (Husslein et al., 2006). Its efﬁcacywas established
in 6 large randomised controlled double blinded trials (French/
Australian Atosiban Investigators, 2001; Goodwin et al., 1994,
1996; Moutquin et al., 2000; Norton et al., 1993; Romero et al.,
2000), however a meta-analysis of these trials involving 1695
women suggested that Atosiban does not reduce the incidence of
preterm birth or improve the neonatal outcome compared with
placebo (Papatsonis et al., 2005).
While the precise mechanisms underpinning human labour
initiation are not fully understood, it is well established that
oxytocin (OT) acting through its G protein-coupled receptor (GPCR)article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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cellular calcium levels. Just prior to the onset of human labour,
uterine sensitivity to OT increases markedly via up-regulation of
the OTR (Fuchs et al., 1982). Binding of OT to its receptor (OTR) leads
to the activation of its heterotrimeric G-proteins Gaq/11 and Gai/o
resulting in the activation of phospholipase C (PLC), hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol
(DAG) and inositol triphosphate (IP3), leading to an increase in
intracellular Ca2þ for Gaq/11, while signalling through Gai/o results in
inhibition of adenylate cyclase activity and a reduction in intra-
cellular cAMP levels (Busnelli et al., 2012; Gravati et al., 2010;
Strakova and Soloff, 1997).
We and others have recently described a role for the OT-OTR
system in the onset of human labour, additional to the stimula-
tion of myometrial contractions, that involves increase in the
expression of COX-2 and other inﬂammatory mediators known to
be associated with the onset of labour (Kim et al., 2015; Pont et al.,
2012). OT-OTR interaction leads to NF-kB activation and subsequent
upregulation of prostaglandins, inﬂammatory chemokines and cy-
tokines that are known to play roles in fetal membrane remodel-
ling, cervical ripening and myometrial activation. Amnion is an
important site of prostaglandin production within the human
uterus (Bennett et al., 1992; Olson, 2003) and its activation is critical
for fetal membrane remodelling, cervical ripening and the stimu-
lation of myometrial contractions (Kim et al., 2015). In this studywe
show that Atosiban fails to inhibit the proinﬂammatory effects of
OT upon human amnion and itself stimulates inﬂammatory
pathway activation in amnion via agonism of Gai.
2. Materials and methods
2.1. Cell preparation and culture
All samples were collected with informed consent. Approval
was granted by the local ethics committee (RREC 2002-6283). Fetal
membranes were obtained from women undergoing elective
caesarean section at term (38e39 weeks of pregnancy), prior to the
onset of labour. Exclusion criteria included pre-existing medical
conditions, multiple pregnancies or treatment with uterotonics.
Amnion epithelial cells were prepared from tissue as previously
described (Bennett et al., 1987).
2.2. Real time polymerase chain reaction (RT-PCR)
Total RNA was extracted by a guanidiumthiocyanate-phenol-
chloroform extraction using RNA STAT-60 reagent (AMS Biotech-
nology) according to the manufacturer's speciﬁcations. Prior to
cDNA synthesis, any DNA contaminations were eliminated by
DNaseI treatment (Invitrogen). The DNaseI treated RNA were used
for ﬁrst-strand cDNA synthesis with SuperScriptII ﬁrst-strand
synthesis kit (Invitrogen). Gene expression was veriﬁed by real-
time PCR performed on ABI StepOne Real Time PCR system
(Applied Biosystems) using SYBR Green I Master mix (Applied
Biosystems). Ampliﬁcation was carried out using speciﬁc primers
for the target DNA, generated using the software Primer Express
(Applied Biosystems). The following gene speciﬁc primers were
used for RT-PCR: L19, 50-GCGGAAGGGTACAGCCAAT-30 and 50-
GCAGCCGGCGCAAA-3’; COX-2, 50-TGTGCAACACTTGAGT-GGCT-30
and 50-ACTTTCTGTACTGCGGGTG-G-3’; IL-6, 50-CCTTCC-AAA-
GATGGCTGAAA-30 and 50-AGCTCTGGCTTGTTCCTCAC-3’; and CCL5,
50-CCATA-TTCCTCGGACACCAC-30 and 50-TGTACTCC-CGAACC-
CATTTC-3’. The data were analysed using Sequence Detector
Version1.7 software (Applied Biosystems). Expression levels were
assessed using the comparative Ct method and the target Ct values
were normalised to ribosomal protein L19 for analysis.2.3. Polymerase chain reaction (PCR)
Polymerase chain reactions (PCR) were performed using Phu-
sion high-ﬁdelity DNA polymerase (New England Biolabs). PCR
reaction mix was prepared following the manufacturer's protocol.
Template DNA were initially denatured for 30 s at 98 C, then the
reactionwas subjected to 30 thermo-cycles of 98 C for 10 s, primer
annealing at 60 C for 30 s and extension at 72 C for 30 s. This was
followed by the ﬁnal extension step of 72 C for 10 min. PCR
products were then analysed by electrophoresis using 1.5e2% (w/v)
agarose gels. The size of DNA fragments were estimated by using a
hyperladder V (Bioline) containing restriction fragments of known
sizes. The bands were imaged using a dark reader (Dark Reader
transilluminator, Clare Chemical Research).
2.4. Protein extraction and Western blot
Cells were lysed on ice for 10 min in radioimmunoprecipitation
assay buffer consisting of 1% Triton X100, 1% Sodium Deoxy-
cholate, 0.1% SDS, 150 mM NaCl, 10 mM Tris (pH 7.4) and 1 mM
EDTA with 1 mM of PMSF, protease and phosphotase inhibitor
cocktail (Thermo-ﬁsher). Lysed samples were centrifuged at 4 C
for 10 min at 13000  g. The resulting supernatant was recovered
and protein concentration determined using the BioRad protein
assay kit. A total of 20 mg of total protein was denatured for 10 min
at 80 C before undergoing electrophoretic separation on a 10%
SDS-polyacrylamide gel for 80min at 140 V. Resolved proteins were
then transferred to PVDF membrane (Millipore) using a wet-
transfer chamber system (BioRad) for 90 min at 300 mA. Mem-
branes were incubated in primary antibodies (detailed below)
overnight at 4 C followed by incubation with HRP-conjugated
secondary antibodies the following day. Signal detection was car-
ried out using ECL plus (GE Amersham Biosciences). To conﬁrm
equal loading of each well, the membranes stripped using 0.2 M
NaOH for 10 min and re-probed for b-actin.
2.5. siRNA gene silencing
Transfection for gene silencing studies was performed using the
Amaxa Nucleofector Technology (Lonza) according to manufac-
turer's protocol. The cell/siRNA suspension was transfected with
30 pmol of siGENOME SMARTpool siRNA (Dharmacon) via elec-
troporation using the Program T-020. Total proteins from the
transfected cells were extracted for further analysis at 72 h.
2.6. ELISA
Concentrations of IL-6, CCL5 and PGE2 released were deter-
mined by a standard ELISA. Supernatants were collected from
treated amnion cultures and immediately frozen at 20 C for
subsequent analysis by ELISA according to manufacturer's in-
structions (R&D systems).
2.7. Antibodies and materials
The following antibodies were obtained from Santa Cruz Bio-
technologies: goat anti-COX-2 (1:2000); anti-Gaq (1:1000) and
HRP-conjugated secondary antibodies raised against goat (1:2000),
rabbit (1:2000), and mouse IgGs (1:2000). Rabbit monoclonal an-
tibodies to p-cPLA2 (1:2000); phospho-p65 (ser536) (1:5000);
phospho-IKKa/b (1:1000); phospho-p38 MAPK (1:1000); phospho-
ERK1/2 (1:5000) and p-SAPK/JNK (1:2000) were from Cell Signal-
ling Technology. The mouse monoclonal anti-b-actin (1:50000);
anti-Gai2 (1:1000) and anti-Gai3 (1:1000) antibodies were from
Abcam. Inhibitors PTX and UBO-QIC were purchased from ENZO
Fig. 1. Atosiban does not inhibit OT-induced proinﬂammatory effects. Pre-labour amnion epithelial cells were treated with Atosiban (10 mM) and OT (100 nM) for 5 min, 15 min,
30 min, 2 h, 4 h and 6 h. Whole cell proteins were subjected to Western blot analyses with antibodies against different phosphorylated NF-kB p65 subunit, ERK1/2 and p38 MAPK
(A), as well as COX-2 and p-cPLA2 (B), and matching densitometry analyses shown as fold changes compared to non-stimulated (NS) controls have been added below the
representative blots. Membranes were probed with b-actin to conﬁrm equal loading (n ¼ 6; *p < 0.05, **p < 0.01 compared with NS, ANOVA).
Fig. 2. Increase in prolabour NF-kB-regulated gene expression with Atosiban stimulation. Pre-labour amnion epithelial cells were treated with Atosiban (10 mM) for 1 h, 2 h, 4 h,
and 6 h. Total RNA was subjected to gene expression analysis for downstream NF-kB regulated genes; COX-2 (A), IL-6 (B) and CCL5 (C) (n ¼ 6; *p < 0.05 compared with NS, ANOVA).
PGE2 (D), IL-6 (E), and CCL5 (F) release was assessed using ELISA (n ¼ 6; *p < 0.05 compared with NS, Freidman's test, followed by Dunn's Multiple Comparisons post hoc test.).
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SMARTpool siRNAs comprised of 3 different siRNAs for Non-
Target (D-001810-01-05), Gaq (L-008562-00-0005), Gai2 (L-
003897-00-0005), and Gai3 (L-005184-00-0005) were purchased
from Dharmacon.
2.8. Statistical analysis
Data sets were tested for normality using the Kolmogor-
oveSmirnov test. For multiple comparisons of normally distributed
data, ANOVA followed by Turkeys or Dunnett's post hoc test was
used. For data that were not normally distributed, multiple com-
parisons were carried out using Freidman's test, followed by Dunn's
Multiple Comparisons post hoc test. All data sets were presented
with standard error of mean (s.e.m) and probability value of
P < 0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. Atosiban fails to inhibit the pro-inﬂammatory effects of OT in
human amnion and instead, stimulates inﬂammation in human
amnion
We have previously shown that the OT/OTR system drivesinﬂammatory activation in human amnion via NF-kB with subse-
quent upregulation of prostaglandins and inﬂammatory chemo-
kines and cytokines (Kim et al., 2015). Incubation of amnion cells
with Atosiban had no signiﬁcant effect upon OT-simulated activa-
tion of NF-kB p65, ERK1/2, or p38 (Fig 1A). Similarly, upregulation
of COX-2 and activation of cPLA2 by OT was unaffected by Atosiban
treatments (Fig 1B). Instead incubation of amnion cells with Ato-
siban alone resulted in activation of NF-kB p65, ERK1/2, and p38
and downstream expression of COX-2 and p-cPLA2 to a similar
degree as seen with OT treatment (Fig 1). We therefore examined
the effect of Atosiban on the expression of down-stream NF-kB
regulated genes. As demonstrated at the protein level, treatment of
amniotic cells with Atosiban alone increased mRNA expression of
COX-2 (Fig 2A) as well as IL-6 and CCL5 (Fig. 2BeC). Atosiban
treatment also led to increased excretion of prostaglandin (PGE2)
and cytokines (IL-6 and CCL5) in cell supernatant as assessed by
ELISA (Fig. 2DeF).
3.2. The pro-inﬂammatory effect of OT in human amnion is via Gai
To gain insight into the molecular mechanisms underlying the
pro-inﬂammatory effects of OT and Atosiban in amnion, we
investigated the role of different G proteins potentially involved in
OT-OTR signalling. In human myometrium, OTR has been shown to
Fig. 3. Gaq inhibitor, UBO-QIC, does not block the pro-inﬂammatory effects of OT. Pre-labour amnion epithelial cells were incubated in UBO-QIC (1 mM) for 2 h prior to 5 min,
15 min or 30 min of OT stimulation (100 nM). Presence of UBO-QIC suppressed the effect of OT upon ERK1/2 phosphorylation, but not p65 and p38. Densitometry plots show no
signiﬁcant changes of p-p65, p-ERK1/2 and p-p38 in comparison to NS controls (A). Western blot analysis of cells pretreated with UBO-QIC (1 mM) for 2 h prior to 2 h, 4 h or 6 h of OT
stimulation (100 nM) showed no signiﬁcant effect on OT-induced COX-2 expression and phosphorylation of cPLA2 in presence of inhibitor. Bar graphs show densitometry analysis of
COX-2 and p-cPLA2 (B). Inhibition of calcium response in human myometrial cells were used as a positive control for UBO-QIC (C) (n ¼ 6; *p < 0.05, **p < 0.01, ***p < 0.001, ANOVA).
S.H. Kim et al. / Molecular and Cellular Endocrinology 420 (2016) 11e2316couple to various G proteins including Gaq/11 and Gai (Phaneuf et al.,
1993). However, the G protein-coupling of OTR in amnion is un-
known. Treatment of amnion samples with the Gaq/11 inhibitor,
UBO-QIC, had no signiﬁcant effect on the OT-induced activation of
NF-kB p65 or p38 (Fig 3A), or upon COX-2 and p-cPLA2 expression
(Fig 3B). Presence of UBO-QIC resulted in a marginal reduction of
OT-induced activation of ERK1/2 (Fig 3A). The efﬁcacy of UBO-QIC
was conﬁrmed by demonstrating successful inhibition of calcium
inﬂux in human myometrial cells (Fig 3C). These ﬁndings were
further conﬁrmed using Gaq/11 targeted RNAi knockdown whereby
down-regulation of Gaq/11 protein did not suppress the OT-induced
activation of NF-kB andMAPKs, as well as subsequent COX-2 and p-
cPLA2 expression (Fig 4).
In contrast, pre-treatment of amnion cells with the Gai inhibitor,
pertussis toxin (PTX), signiﬁcantly reduced OT-stimulated NF-kB
activation and to a lesser extent MAPK activation (Fig 5A). Presence
of PTX inhibited subsequent OT-induced upregulation of COX-2 and
p-cPLA2 protein levels (Fig 5B). Three subtypes of human Gai pro-
teins have been identiﬁed to date; Gai1, Gai2 and Gai3 (Hurowitz
et al., 2000). RT-PCR analysis of the Gai subtypes revealed that Gai2
and Gai3 are expressed in amnion but not Gai1 (Fig 6). To deter-
mine the role of speciﬁc Gai subtypes in human amnion, cells were
transfected with Gai2 or Gai3 targeted siRNA. Transient down-
regulation of Gai2 led to the attenuation of OT-induced activa-
tion of MAPKs, NF-kB and downstream COX-2 expression
(Fig. 7AeG). Down-regulation of Gai2 also resulted in reduction of
OT-induced p-cPLA2 expression, however this did not reach sig-
niﬁcance. Similarly, down-regulation of Gai3 suppressed OT-
induced activation of p38 and COX-2 expression, but unlike Gai2,Fig. 4. Transient knockdown of Gaq does not affect the OT-mediated pro-inﬂammatory
target siRNA were treated with OT (100 nM) for 5 min, 15 min, 30 min, 2 h, 4 h and 6 h. Who
to conﬁrm Gaq knockdown with Gaq-target siRNA transfection. siRNA knockdown of Gaq had
cPLA2 (B). Densitometry plots of p-p65 (C), p-ERK1/2 (D), p-p38 (E), COX-2 (F) and p-cPLA2 (G
target siRNA transfected cells (n ¼ 3; a p < 0.05 compared with NS of non-target siRNA tra
ANOVA).knockdown of Gai3 showed no signiﬁcant effect on NF-kB, ERK1/2
and downstream p-cPLA2 expression (Fig. 8AeG). Inhibition of OT-
induced inﬂammatory activationwas observed with both Gai2 and
Gai3 down-regulation, however, it was most prominent with Gai2
knockdown suggesting a major role for Gai2 in OT-mediated in-
ﬂammatory effects.3.3. G protein signalling bias of Atosiban in human amnion
Recent studies have suggested that Atosiban is a biased ligand
that antagonises Gaq/11 signalling whilst acting as a Gai agonist in
various cell lines (Busnelli et al., 2012; Reversi et al., 2005).
Therefore, we employed Atosiban as a tool to speciﬁcally activate
OTR-mediated Gai signalling in human amnion. To demonstrate
whether Atosiban exhibits G protein signalling bias in human
amnion, we investigated the Gai-dependence of Atosiban-induced
inﬂammatory responses. Presence of PTX completely blocked
Atosiban-induced activation of NF-kB p65 and ERK1/2, and
although there was a reduction in p38 activation, it did not reach
signiﬁcance (Fig 9A). PTX also suppressed Atosiban-mediated
expression of COX-2 and p-cPLA2 (Fig 9B). With targeted-
knockdown of Gai2 proteins, the effects of Atosiban on the acti-
vation of p38, and expression of COX-2 and p-cPLA2 appears to be
attenuated (Fig. 10AeG). However, only Gai3 knockdown resulted
in signiﬁcant decreases in Atosiban-induced activation of NF-kB,
p38 and downstream COX-2 expression (Fig. 11AeG). These results
suggest that Gai3 protein plays a more signiﬁcant role in Atosiban-
induced activation of inﬂammatory mediators.effects. Pre-labour amnion epithelial cells transfected with non-target siRNA or Gaq-
le cell extracts were subjected to Western blot analyses with antibodies against Gaq (A)
no effect on OT-induced activation of NF-kB and MAPKs, or expression of COX-2and p-
) show no signiﬁcant difference in the effects of OT between non-target siRNA and Gaq-
nsfected cells (Nt), b p < 0.05 compared with NS of Gaq-target siRNA transfected cells,
Fig. 5. Gai inhibitor, PTX, suppresses the pro-inﬂammatory effects of OT. Pre-labour amnion epithelial cells were incubated in PTX (0.2 mg/ml or 0.5 mg/ml) for 30 min prior to
15 min or 30 min of OT stimulation (100 nM). Presence of PTX suppresses the effect of OT upon p65, ERK1/2, and p38 phosphorylation. Densitometry analyses show signiﬁcant
decreases in OT-induced p-p65, p-ERK1/2 and p-p38 expression in presence of PTX (A). Western blot analysis of cells pretreated with PTX (0.2 mg/ml or 0.5 mg/ml) for 30 min prior to
4 h or 6 h of OT stimulation (100 nM) demonstrated inhibition of OT-induced COX-2 expression and phosphorylation of cPLA2 in presence of PTX. Bar graphs show densitometry
analysis of COX-2 and p-cPLA2 (B) (n ¼ 6; *p < 0.05, **p < 0.01, ANOVA).
Fig. 6. Human amnion expresses different subtypes of Gai proteins. Pre-labour amnion epithelial cells were established from 5 different samples. cDNAs were synthesized using
total RNA extracted from non-stimulated amnion cells. Products of PCR reactions with primers speciﬁc for Gai1, Gai2 and Gai3 were analysed on 2% agarose gel. Gai1 (A) was not
detectable in amnion, however, the expression of Gai2 (B) and Gai3 (C) were observed. Myometrial cDNA was used as positive controls (þ) (expected product sizes; Gai1 115 bp,
Gai2 212 bp and Gai3 154 bp).
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While the OTR antagonist Atosiban has a well-described role in
the modulation of myometrial contractility its effect on other
gestational tissues is unknown. In this study we demonstrate that
Atosiban, a mixed OTR/V1a antagonist widely used as a tocolytic
drug, acts as a biased ligand in amnion cells. It fails to inhibit the
activation of pro-inﬂammatory mediators stimulated by oxytocin,
and, in the absence of OT it activates the same pro-labour inﬂam-
matory pathways as OT. Treatment of amnion cells with Atosiban
had no effect upon OT-mediated activation of NF-kB p65, ERK1/2,Fig. 7. Gai¡2 signalling play a major role in the regulation of OT-induced proinﬂammat
Gai2-target siRNA were treated with OT for 5 min, 15 min, 30 min, 2 h, 4 h and 6 h. Whole ce
conﬁrm Gai2 knockdown with Gai2-target siRNA transfection. siRNA knockdown of Gai
Densitometry plots of p-p65 (C), p-ERK1/2 (D), p-p38 (E), COX-2 (F) and p-cPLA2 (G) show si
Gai2-target siRNA transfection (n ¼ 3; a p < 0.05 compared with NS of Nt, b p < 0.05 compa
transfected cells, ANOVA).and p38 or expression of COX-2 and cPLA2. Moreover, Atosiban
treatment alone resulted in activation of NF-kB, ERK1/2 and p38
and downstream expression of COX-2, CCL5, IL-6 and PGE2.
Human parturition is associated with an inﬂammatory cascade
that involves elevation of inﬂammatory cytokines (eg IL-1b, IL-6
and TNFa) and chemokines (eg IL-8, CCL2 and CCL5) both in
amnion and myometrium (Osman et al., 2003; Shynlova et al.,
2013). Amnion is a major site of prostaglandin and pro-
inﬂammatory cytokine and chemokine release leading to cervical
ripening and fetal membrane remodelling (Kim et al., 2015).
Persistent activation of pro-inﬂammatory pathways in humanory response. Pre-labour amnion epithelial cells transfected with non-target siRNA or
ll extracts were subjected to Western blot analyses with antibodies against Gai2 (A) to
2 suppressed OT-induced activation of NF-kB and MAPKs, or expression of COX-2 (B).
gniﬁcant decrease in OT-induced activation of NF-kB and MAPKs, as well as COX-2 with
red with NS of Gai2-target siRNA transfected cells, c p < 0.05 Nt vs Gai2-target siRNA
Fig. 8. The OT-mediated activation of NF-kB and MAPKs, and downstream PG synthetic enzyme expression involve Gai¡3 signalling. Pre-labour amnion epithelial cells
transfected with non-target siRNA or Gai3-target siRNA were treated with OT for 5 min, 15 min, 30 min, 2 h, 4 h and 6 h. Whole cell extracts were subjected to Western blot
analyses with antibodies against Gai3 (A) to conﬁrm Gai3-knockdown with Gai3-target siRNA transfection. siRNA knockdown of Gai3 reduced OT-induced expression of COX-2
but had a lesser effect on the OT-induced activation of NF-kB and MAPKs (B). Densitometry plots of p-p65 (C), p-ERK1/2 (D), p-p38 (E), COX-2 (F) and p-cPLA2 (G) show a decrease in
OT-induced activation of p38 and expression of COX-2, but not in OT-induced activation of NF-kB or ERK1/2 with Gai3-target siRNA transfection (n ¼ 3; a p < 0.05 compared with
NS of Nt, b p < 0.05 compared with NS of Gai3-target siRNA transfected cells, ANOVA).
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of labour.We have hypothesised that fetal membrane activation is a
committing step on the pathway to the onset of labour, resolved
only when the fetal membranes are expelled following delivery
with the placenta (Lim et al., 2012). We have shown increased
expression of OTR in amnion correlates with activation of NF-kB,
and that OT treatment of both amnion and myometrial cells acti-
vates a similar cassette of inﬂammatory mediators suggesting that
OT acts as an endogenous inﬂammatory signalling molecule, and
potentially plays a role in the activation of amnion which occurs
pre-labour (Kim et al., 2015).
OTRs are coupled to both Gaq and Gai that collectively regulate
diverse cellular functions through complex signalling pathways.
While the subtypes of G proteins involved in OT-induced COX-2
expression in myometrium are well described (Phaneuf et al., 1996,
1993; Zhou et al., 2006), they have not been investigated in human
amnion. A study in rabbit amnion reported that OT-induced Ca2þ
response and activation of ERK1/2 is Gaq-dependent (Jeng et al.,
2000). Further studies conﬁrming the signiﬁcance of Ca2þ
response and Gaq linked Ca2þ signalling in OT-initiated pro-in-
ﬂammatory effects in human amnion are required to clarify the
tissue-speciﬁc signalling properties of OT/OTR system. However,
the results in this study indicate that OT-initiated pro-inﬂamma-
tory signal transduction in human amnion epithelial cells is majorly
Gai-dependent. Under conditions where Gaq proteins were down-
regulated by targeted siRNA transfection, OT-induced activation
of MAPKs and NF-kB and subsequent COX-2 and p-cPLA2 expres-
sions were not affected, suggesting that OTR-Gaq coupling is not
required to propagate OT-induced pro-inﬂammatory signalling inhuman amnion. Reduced concentrations of Gaq proteins are asso-
ciated with compensatory changes in the levels of other G proteins
including Gai (Krumins and Gilman, 2006). However, this
compensatory effect can be excluded as we did not observe any
changes in the other G protein expressions with Gaq knockdowns.
The Gai inhibitor, PTX, has partial inhibitory effects in rat and
humanmyometrium (Phaneuf et al., 1993; Zhou et al., 2006). In our
study OT-induced MAPK and NF-kB activation as well as COX-2 and
p-cPLA2 protein levels were markedly reduced by PTX indicating a
key role for Gai in OT signalling. However, as PTX does not
discriminate between different Gai subtypes, we used Gai targeted
siRNA knockdown to deﬁnitively demonstrate the functional
requirement of Gai2 and 3 subtypes in response to OT stimulation.
Down-regulation of Gai-2 blocked OT-induced activation of NF-kB
and MAPK, as well as expression of COX-2. However, OT-mediated
ERK activation and p-cPLA2 expression was not completely inhibi-
ted by the knockdown of Gai2. This could possibly be due to the
involvement of b-arrestin signalling which can activate ERK1/2
independent of G proteins (Shenoy et al., 2006) resulting in p-cPLA2
expression. Gai3 targeted knockdown only inhibited the rapid
activation of MAPKs and COX-2 expression but to a lesser extent.
These data demonstrate that Gai2 and not Gaq signalling plays a
signiﬁcant role in mediating these OT-induced responses leading to
a sequential activation of MAPKs and NF-kB and subsequent in-
ﬂammatory pathway activation that promotes the labour pheno-
type in human amnion.
Busnelli et al. have recently reported that Atosiban induces a
signiﬁcant activation of the Gai3 but not Gaq subunit in
HEK293 cell lines stably transfected with the human OTR cDNA
Fig. 9. Gai inhibitor, PTX, suppresses Atosiban-induced activation of NF-kB and MAPKs, as well as COX-2 and p-cPLA2 expression. Pre-labour amnion epithelial cells were
incubated in PTX (0.2 mg/ml or 0.5 mg/ml) for 30 min prior to 15 min or 30 min of Atosiban stimulation (10 mM). Presence of PTX suppresses the effect of Atosiban upon p65, ERK1/2,
and p38 phosphorylation. Bar graphs show densitometry analyses of p-p65, p-ERK1/2 and p-p38 (A). Western blot analysis of cells pretreated with PTX (0.2 mg/ml or 0.5 mg/ml) for
30 min prior to 4 h or 6 h of Atosiban stimulation (10 mM) demonstrated inhibition of Atosiban-induced COX-2 expression and phosphorylation of cPLA2 in presence of PTX. Bar
graphs show densitometry analyses of COX-2 and p-cPLA2 (B) (n ¼ 6; *p < 0.05, **p < 0.01, ***p < 0.001, ANOVA).
S.H. Kim et al. / Molecular and Cellular Endocrinology 420 (2016) 11e2320(Busnelli et al., 2012). Consistent with these ﬁndings we demon-
strate that this also applies to primary amnion cells with endoge-
nous OTR expression. While the primary effect of Atosiban in the
myometrium may be OTR antagonism of Gaq mediated signalling
and decreased contractility by suppressing PLC activation and IP3
and DAG production further affecting phosphorylation anddownstream transcriptional activity our results suggest Atosiban
concurrently activates inﬂammation via Gai in the amnion and
consequently promotes a labouring phenotype. Further studies will
need to deﬁne tissue speciﬁc differences in Gaq and Gai activation.
In this study we have found that in amnion the Atosiban-induced
activation of NF-kB p65 and ERK1/2 were PTX-sensitive and
Fig. 10. Gai¡2 signalling is involved in Atosiban-induced activation of NF-kB and MAPKs, as well as COX-2 and p-cPLA2 expression. Pre-labour amnion epithelial cells
transfected with non-target siRNA or Gai2target siRNA were treated with Atosiban for 5 min, 15 min, 30 min, 2 h, 4 h and 6 h. Whole cell extracts were subjected to Western blot
analyses with antibodies against Gai-2 (A) to conﬁrm Gai2-knockdown with Gai2-target siRNA transfection. siRNA knockdown of Gai2 reduced Atosiban-induced expression of
COX-2 but had a lesser effect on the Atosiban-induced activation of NF-kB and MAPKs (B). Densitometry plots of p-p65 (C), p-ERK1/2 (D), p-p38 (E), COX-2 (F) and p-cPLA2 (G) show
a decrease in Atosiban-induced activation of p38 and expression of COX-2, but not in Atosiban-induced activation of NF-kB or ERK1/2 with Gai2-target siRNA transfection (n ¼ 3; a
p < 0.05 compared with NS of Nt, b p < 0.05 compared with NS of Gai2-target siRNA transfected cells, ANOVA).
Fig. 11. Gai¡3 signalling plays a major role in the regulation of Atosiban-induced activation of NF-kB and MAPKs, as well as COX-2 and p-cPLA2 expression. Pre-labour amnion
epithelial cells transfected with non-target siRNA or Gai3-target siRNA were treated with Atosiban for 5 min, 15 min, 30 min, 2 h, 4 h and 6 h. Whole cell extracts were subjected to
Western blot analyses with antibodies against Gai¡3 (A) to conﬁrm Gai3knockdown with Gai3-target siRNA transfection. siRNA knockdown of Gai2 suppressed OT-induced
activation of NF-kB and MAPKs, or expression of COX-2 (B). Densitometry plots of p-p65 (C), p-ERK1/2 (D), p-p38 (E), COX-2 (F) and p-cPLA2 (G) show signiﬁcant decrease in
Atosiban-induced activation of NF-kB and p-p38, as well as COX-2 with Gai3-target siRNA transfection (n ¼ 3; a p < 0.05 compared with NS of Nt, b p < 0.05 compared with NS of
Gai3-target siRNA transfected cells, c p < 0.05 Nt vs Gai3-target siRNA transfected cells, ANOVA).
S.H. Kim et al. / Molecular and Cellular Endocrinology 420 (2016) 11e2322down-regulation of Gai2 or Gai3 proteins resulted in decreases in
Atosiban-induced downstream COX-2 expression.
Our data suggest that Atosiban acts as an anti-labour agent
through inhibition of OT-induced contractions in the myometrium
but as a pro-labour agent in the amnion resulting in activation of
inﬂammation via differential OTR G-protein coupling. Previous
studies have shown that GPCR agonists/antagonists can activate
diverse signalling pathways by inducing conformational changes in
their receptors (Kenakin, 2001) and can result in alteration of the
receptor (possibly via phosphorylation) to a non-active conforma-
tional state (Gether et al., 1997). Therefore the biased agonism of
Atosiban we describe in the amnion via OTR-speciﬁc Gai coupling
could possibly be a result of such OTR structural changes. These
contradictory actions of Atosiban may reduce its potency as a
tocolytic. Oxytocin receptor antagonists that inhibit both OT
induced contractions and inﬂammation are likely to be more
effective.
Fetal concerns regarding the use of Atosiban are discussed in the
literature mainly based on the results of the Atosiban versus pla-
cebo trial by Romero and co-workers (Romero et al., 2000) who
found a higher rate of fetal-infant death in the Atosiban treated
group in extremely premature infants. There was however a sig-
niﬁcant imbalance in randomisation at gestational ages with more
very preterm infants being exposed to Atosiban. Atosiban crosses
the placenta with an average fetal versus maternal ratio of 0.124
(Valenzuela et al., 1995) and concentrations of Atosiban do not
appear to accumulate in the fetus. Romero and colleagues had
previously hypothesized that the anti-vasopressin effects of Atosi-
ban could have altered fetal responses to stress and therefore could
have contributed to the poor outcome in the extremely preterm
infants. However maternal and fetal cardiovascular parameters are
not signiﬁcantly altered when Atosiban is administered in pregnant
sheep (Greig et al., 1993) and fetal oxygenation remains the same
after Atosiban infusion in chronically instrumented baboons
(Nathanielsz et al., 1997). Nevertheless, given the association be-
tween inﬂammation and poor neonatal outcome, activation or
exacerbation of inﬂammation is not a desirable effect of any agent
to be used in the context of acute preterm labour. It is therefore
critical that therapeutics designed to modulate the OT/OTR system
for the management of term and preterm labour take into account
the effects of differential G-protein coupling of the OTR and the role
of OT and selective OTR agonists/antagonists in the activation of
pro-inﬂammatory pathways.
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